# Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Source: https://onco.cc/trials/nct03947385/  
OnCo record `nct03947385` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Darovasertib, Binimetinib, Crizotinib in melanoma and uveal melanoma, run by IDEAYA Biosciences, now recruiting.

## Summary

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions is a phase 1/2 interventional study registered as NCT03947385 by IDEAYA Biosciences, with 336 participants planned, started 2019-06-28 and due to reach its primary completion in 2027-01-29. Interventions recorded: IDE196, Binimetinib, Crizotinib. Conditions listed: Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT03947385
- Phase: 1/2
- Setting: A Phase 1/2 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
- Sponsor: IDEAYA Biosciences
- Enrolled: 336

## Sources

- ClinicalTrials.gov NCT03947385: https://clinicaltrials.gov/study/NCT03947385

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Melanoma](https://onco.cc/cancers/melanoma/), [Uveal melanoma](https://onco.cc/cancers/uveal-melanoma/)
- drugs: [Binimetinib](https://onco.cc/drugs/binimetinib/), [Crizotinib](https://onco.cc/drugs/crizotinib/), [Darovasertib](https://onco.cc/drugs/darovasertib/)
- companies: [IDEAYA Biosciences](https://onco.cc/companies/ideaya-biosciences/)

---
JSON: https://onco.cc/api/v1/entities/nct03947385.json